argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference: A Look Ahead

argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:45 a.m. PT. The presentation will be accessible via a live webcast on the Investors section of the argenx website at , with a replay available for approximately 30 days following the presentation.

This presentation comes at a critical juncture for argenx, as the company continues to execute on its ambitious business plan and expand its global reach. In 2023, argenx reported global net product sales of $1.2 billion, operating loss of $425 million, and a strong cash position of $3.2 billion. The company's financial performance in 2023 has set the stage for its strategic priorities in 2024, including reaching more patients with VYVGART, advancing its pipeline through new data readouts, and leveraging its repeatable innovation engine through the Immunology Innovation Program (IIP).


Table showing argenx's financial performance in 2023:
| Revenue | Operating Loss | Cash Position |
| --- | --- | --- |
| $1.2 billion | $425 million | $3.2 billion |


argenx's presentation at the J.P. Morgan Healthcare Conference will provide an opportunity for investors to gain insights into the company's strategic priorities, pipeline progress, and financial outlook. The company's strong cash position and commitment to innovation will likely be key topics of discussion, as argenx continues to invest in its pipeline and expand its global reach.

In addition to its presentation at the J.P. Morgan Healthcare Conference, argenx has several ongoing clinical trials and pipeline candidates that investors should keep an eye on. The company is evaluating efgartigimod in multiple serious autoimmune diseases, including generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and thyroid eye disease (TED). argenx is also advancing its pipeline through new data readouts and plans to submit four new INDs by the end of 2025.

argenx pipeline candidates

In conclusion, argenx's presentation at the 43rd Annual J.P. Morgan Healthcare Conference is an important event for investors to stay informed about the company's strategic priorities, pipeline progress, and financial outlook. With a strong cash position and commitment to innovation, argenx is well-positioned to continue executing on its business plan and expanding its global reach in the immunology space. Investors should closely monitor the company's progress and consider the opportunities that lie ahead.